A carregar...
Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain
Elagolix is a novel oral gonadotropin releasing hormone receptor antagonist, that can suppress estradiol in a dose‐dependent manner. It is indicated for management of moderate‐to‐severe pain associated with endometriosis. A population exposure‐response model describing the relationship between elago...
Na minha lista:
| Publicado no: | CPT Pharmacometrics Syst Pharmacol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7679073/ https://ncbi.nlm.nih.gov/pubmed/32945631 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12560 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|